SCHEMBL14189677

SCHEMBL14189677

Cc1ccc2nc(NC=N)sc2c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 11/20 0.57
▸ LMNA P02545 1/20 0.57
▸ DYRK1A Q13627 1/20 0.57
▸ RAB9A P51151 11/20 0.51
▸ MAPT P10636 6/20 0.51
▸ SMN1; SMN2 Q16637 6/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ KDM4E B2RXH2 4/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ NFKB1 P19838 2/20 0.51
▸ NFKB2 Q00653 2/20 0.51
▸ RELA Q04206 2/20 0.51
▸ TP53 P04637 3/20 0.50
▸ ACP1 P24666 1/20 0.50
▸ PTPN1 P18031 1/20 0.49
▸ APP P05067 4/20 0.49
▸ SNCA P37840 1/20 0.49
▸ TDP1 Q9NUW8 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14189675 0.84 NPC1 (0.61) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL13151088 0.80 NPC1 (0.64) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL2115626 0.78 NPC1 (0.65) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL21914837 0.78 NPC1 (0.62) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL14189678 0.76 DYRK1A (0.73) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL18058957 0.75 NPC1 (0.59) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL11265618 0.75 NPC1 (0.71) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL14184989 0.75 NPC1 (0.59) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL8019525 0.75 NPC1 (0.59) NPC1LMNADYRK1ARAB9AMAPT
SCHEMBL10672271 0.75 NPC1 (0.55) NPC1LMNADYRK1ARAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080118969-A1 BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE LLC (US) 2008-05-22 — — US disclosed
US-20080118969-A1 BIS-AMINO ACID HYDROXYETHYLAMINO SULFONAMIDE RETROVIRAL PROTEASE INHIBITORS G.D. SEARLE LLC (US) 2008-05-22 — — US disclosed
US-7339078-B2 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors G.D. SEARLE LLC (US) 2008-03-04 — — US disclosed
US-20070037754-A1 Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide G.D. SEARLE & CO. (US) 2007-02-15 — — US disclosed
US-7161033-B2 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors G. D. SEARLE & CO. (US) 2007-01-09 — — US disclosed
US-7161033-B2 Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors G. D. SEARLE & CO. (US) 2007-01-09 — — US disclosed
US-20070004646-A1 Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors G.D. SEARLE & CO. (US) 2007-01-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037754-A1 Inhibitors of HIV protease; 2S-[[(N-methylamino)acetyl]amino]-N-[2R-hydroxy-3-[[(1,3-benzodioxol-5-yl)sulfonyl](2-methylpropyl)amino)-1S-(phenylmethyl)propyl]-3,3-dimethyl-butanamide DNPEP, PREP, ANPEP NPC1 2137/4885LMNA 678/4885DYRK1A 4615/4885
US-20070004646-A1 Heterocyclecarbonyl amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors DNPEP, PREP, ANPEP NPC1 2716/4885LMNA 3268/4885DYRK1A 4565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback